Butterfly Network vs PathAI

Butterfly Network has a disclosed valuation of $1.5B, while PathAI's valuation is not publicly available, making a direct size comparison difficult. Butterfly Network employs 500-1000 people.

Butterfly Network has raised more in total funding at $700M, compared to PathAI's $255M — a gap of $445M. Combined, the two companies have completed 3 known funding rounds.

Butterfly Network holds the higher Awaira Score at 85/100, compared to PathAI's 62/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 23-point gap that reflects meaningful differences in scale or traction.

Butterfly Network was founded by John Martin in 2011. PathAI was founded by Andy Beck in 2016. Visit each company's profile on Awaira for a full founder biography.

Butterfly Network: Butterfly Network produces the Butterfly iQ, a handheld ultrasound device powered by a proprietary semiconductor chip that replaces traditional piezoelectric transducer arrays with a single silicon chip capable of whole-body imaging. The AI software layer provides real-time image interpretation guidance, enabling clinicians with limited ultrasound training to perform diagnostic scans at the bedside.\n\nThe company is publicly traded on the NYSE under the ticker BFLY and raised over 700 million USD prior to and through its public listing. Butterfly has deployed devices across hospitals, emergency rooms, and point-of-care settings in over 50 countries, with particular penetration in resource-limited healthcare settings where traditional ultrasound equipment is prohibitively expensive or unavailable.\n\nPortable AI-assisted diagnostic imaging represents a structural shift in how and where medical imaging is performed. Butterfly Network has created a defensible position through its proprietary chip architecture, which competitors cannot easily replicate, and through its growing library of AI-assisted clinical guidance tools. The transition from hospital-based imaging to point-of-care diagnostics powered by AI guidance is a multi-decade trend that positions Butterfly at the center of a fundamental change in diagnostic medicine. PathAI: PathAI is an AI healthcare company founded in 2016 that develops digital pathology solutions and AI-powered diagnostic tools for pathology labs and healthcare institutions. The company specializes in machine learning algorithms designed to assist pathologists in analyzing tissue samples and identifying diseases, particularly cancer. PathAI's core technology platform leverages deep learning and computer vision to process histopathology images, enhancing diagnostic accuracy and workflow efficiency. The company's primary offering includes software that integrates with existing laboratory information systems, enabling pathologists to use AI-assisted analysis for specimen evaluation. PathAI has developed partnerships with major healthcare systems and diagnostic laboratories, demonstrating clinical utility in oncology and other pathology specialties. The platform addresses critical challenges in pathology including diagnostic consistency, workload management, and access to specialized expertise in underserved regions. PathAI has raised $255 million in total funding as of its Series C stage, with valuation not disclosed. The company operates in the competitive digital pathology and AI diagnostics space, alongside competitors offering similar computational pathology solutions. The digital pathology market is experiencing significant growth driven by increasing diagnostic demands, laboratory automation trends, and regulatory acceptance of AI-assisted tools. PathAI's trajectory reflects broader momentum in AI-enabled healthcare diagnostics and precision medicine applications. PathAI combines deep learning with pathology workflows to create clinically integrated AI tools that assist rather than replace human pathologists.

Butterfly Network was founded first in 2011, giving it 5 years of additional market experience. PathAI was founded later in 2016. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Butterfly Network has approximately 500-1000 employees, while PathAI has approximately 300. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Butterfly Network and PathAI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.